TBPH - Theravance Biopharma, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
18.26
-0.94 (-4.90%)
At close: 4:00PM EDT

18.26 0.00 (0.00%)
After hours: 4:59PM EDT

Stock chart is not supported by your current browser
Previous Close19.20
Open18.95
Bid17.80 x 1100
Ask18.22 x 1100
Day's Range17.87 - 18.95
52 Week Range17.87 - 35.48
Volume401,331
Avg. Volume268,159
Market Cap1.025B
Beta (3Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-4.10
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.43
Trade prices are not sourced from all markets
  • Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
    Zacks2 days ago

    Lilly's Crohn's Disease Candidate Meets Phase II Study Goals

    Lilly's (LLY) mirikizumab met primary endpoint and key secondary endpoints in phase II Crohn's disease study.

  • PR Newswire3 days ago

    Theravance Biopharma Reports Data from Phase 1b Study of TD-1473 in Oral Presentation at Digestive Disease Week (DDW) 2019

    Numerically higher rates of clinical response were observed for TD-1473 after four weeks of treatment as compared to placebo. Clinical response, which was defined as a reduction in total Mayo score of ≥ 3 points and ≥ 30%, with a reduction in rectal bleeding subscore by ≥ 1 point or an absolute rectal bleeding subscore of ≤ 1 point, was achieved by 2 of 10 patients (20%) in the 20 mg cohort, 2 of 10 patients (20%) in the 80 mg cohort, and 6 of 11 patients (55%) in the 270 mg cohort, compared to 1 of 9 patients (11%) in placebo group.

  • PR Newswire4 days ago

    Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International Conference

    DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, May 20, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced the presentation of data from its pivotal Phase 3 efficacy studies and a 52-week safety study at the 2019 American Thoracic Society (ATS) International Conference in Dallas, Texas. YUPELRI® (revefenacin) inhalation solution, a long-acting muscarinic antagonist (LAMA), is the first and only once-daily, nebulized bronchodilator approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in the U.S.

  • Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript
    Motley Fool9 days ago

    Theravance Biopharma Inc. (TBPH) Q1 2019 Earnings Call Transcript

    TBPH earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of TBPH earnings conference call or presentation 7-May-19 9:00pm GMT

    Q1 2019 Theravance Biopharma Inc Earnings Call

  • PR Newswire10 days ago

    Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral Presentation at Digestive Disease Week (DDW) 2019

    DUBLIN, May 14, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that results from the Company's Phase 1b study of TD-1473 in patients with moderately-to-severely active ulcerative colitis will be the focus of an oral presentation at Digestive Disease Week (DDW) 2019.  The presentation will highlight final data from the Phase 1b clinical trial of TD-1473 in patients with moderately-to-severely active ulcerative colitis.  These findings demonstrate signals of clinical and biomarker activity for TD-1473 suggesting localized target engagement, as well as minimal systemic exposure and no evidence of systemic immunosuppression or infections.  DDW 2019 is being held May 18-21, 2019 in San Diego, CA.

  • Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates
    Zacks15 days ago

    Theravance (TBPH) Q1 Loss Widens, Revenues Miss Estimates

    Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.

  • Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates
    Zacks16 days ago

    Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of -11.86% and -67.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    Theravance Bio: 1Q Earnings Snapshot

    On a per-share basis, the George Town, Cayman Islands-based company said it had a loss of $1.32. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • PR Newswire16 days ago

    Theravance Biopharma, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update

    - Late-stage clinical studies of TD-1473 and ampreloxetine underway - Phase 1 results including biomarker data in asthmatics for lung-selective inhaled pan-JAK inhibitor TD-8236 expected in third quarter ...

  • Markit17 days ago

    See what the IHS Markit Score report has to say about Theravance Biopharma Inc.

    Theravance Biopharma Inc NASDAQ NMS:TBPHView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for TBPH with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $2.81 billion over the last one-month into ETFs that hold TBPH are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Here’s What Hedge Funds Think About Theravance Biopharma Inc (TBPH)
    Insider Monkey21 days ago

    Here’s What Hedge Funds Think About Theravance Biopharma Inc (TBPH)

    How do we determine whether Theravance Biopharma Inc (NASDAQ:TBPH) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • PR Newswire23 days ago

    Theravance Biopharma to Report First Quarter 2019 Financial Results on May 7

    DUBLIN, Ireland, April 30, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended March 31, 2019 and provide a business update after market close on Tuesday, May 7, 2019. To participate in the live call by telephone, please dial (855) 296-9648 from the US, or (920) 663-6266 for international callers, using the confirmation code 9890346. A replay of the conference call will be available on Theravance Biopharma's website for 30 days through June 6, 2019.

  • Read This Before Buying Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares
    Simply Wall St.last month

    Read This Before Buying Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares...

  • PR Newswire2 months ago

    Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference

    DUBLIN, Ireland , April 2, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in a fireside chat at the 18 th Annual Needham Healthcare ...

  • Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report?
    Zacks2 months ago

    Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire2 months ago

    Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress

    DUBLIN, March 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced that data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd European Neurology Congress. Ampreloxetine is an investigational, once-daily norepinephrine reuptake inhibitor (NRI) in development for the treatment of patients with symptomatic neurogenic orthostatic hypotension (nOH).

  • Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
    Zacks2 months ago

    Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

    Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.

  • PR Newswire2 months ago

    Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis

    DUBLIN, March 12, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2b/3 study of TD-1473 in patients with moderately to severely active ulcerative colitis. TD-1473 is a novel, orally administered and gut-selective pan-Janus kinase (JAK) inhibitor in clinical development as a treatment for multiple inflammatory intestinal diseases. In contrast to other oral JAK inhibitors under development or approved for inflammatory bowel disease, TD-1473 is specifically designed to act locally at the site of inflammation in the intestinal wall with minimal systemic exposure.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of TBPH earnings conference call or presentation 26-Feb-19 10:00pm GMT

    Q4 2018 Theravance Biopharma Inc Earnings Call

  • Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
    Zacks3 months ago

    Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.

  • Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 months ago

    Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript

    TBPH earnings call for the period ending December 31, 2018.